• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Lemarus Tebakwani Lukeno

Home > Stories

Lemarus Tebakwani Lukeno

Young man in a hospital in Kenya
Lemarus Tebakwani Lukeno, 23yrs old, is a Kala Azar patient at the DNDI clinical trial site in Baringo, Chemolingot (Kenya).
2 Feb 2012

Kenya

It’s early on the morning of Thursday, 23 August 2012. We are at the Chemolingot Sub-district Hospital, where SSG&PM treatment is being administered to patients suffering from kala-azar (visceral leishmaniasis). In one of the wards, sitting on a hospital bed, is Lemarus Tebakwani Lukeno, a 23-year-old kala-azar patient, who has been undergoing treatment for five days.

Lemarus is from Kisitei, located in Kenya’s East Pokot District, where his livelihood is that of a pastoralist, honey keeper, and farmer. While suffering from kala-azar symptoms, he walked 30 km, which was halfway to the hospital and took public transportation for the rest of the journey (another 30 km).

Lemarus looks into the distance as he waits for the ward round to begin. It is 8:30 a.m. and soon all the kala-azar patients will get the first SSG&PM medication for the day.

‘I have been suffering from kala-azar for two months. I used to take herbal medicines – this was my mother´s advice. At the time, we did not know how to treat the disease since no one in my family had suffered from kala-azar. So we did what we knew best; taking herbal medicine was the only known option. In my community, people suffer from kala-azar, I was lucky that one of our neighbours told me about the clinic where he had undergone treatment for kala-azar. That is what led me to this place [Chemolingot Sub-district Hospital].

When I arrived here the first morning, I received my injection I felt such a relief from my symptoms. My fever, headache, and weakness reduced. I have been here for five days and I am glad that the treatment will only take 17 days because economically this disease has affected me negatively. I am not working. In addition, herbal remedies were expensive: I spent over 10,000 shillings on these traditional medicines. However, when I came to the clinic I only paid twenty shillings and I am getting better. If I ever meet someone with kala-azar, I will not hesitate to recommend this clinic. The treatment works.

My hope in the future is that I get back to my routine. Right now everything back home is on hold, all my responsibilities.’

Visceral leishmaniasis Kenya

Read, watch, share

Loading...
Press releases
4 Nov 2025

European Commission invests EUR 20 million to develop urgently-needed medicines against dengue in partnership with AFD and DNDi

Woman in rural village
Publications
29 Oct 2025

Chagas Platform Newsletter N°15

Jessica Robbins
Stories
24 Oct 2025

Jessica Robbins: A long and difficult journey with cutaneous leishmaniasis

Videos
24 Oct 2025

Road to Elimination of Kala-azar in South Asia

Videos
22 Oct 2025

The Boy Who Beat the Sandfly

News
14 Oct 2025

Twenty years of the Regional Kala-azar Elimination Initiative in South Asia

Viewpoints
9 Oct 2025

Pharma’s shift away from infectious disease research could spell disaster for the world’s poorest people

STAT
News
3 Oct 2025

DNDi 2025 Projects of the Year recognize contributions of DNDi teams and partners working to deliver urgently needed innovations for people affected by Chagas disease and river blindness

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license